# SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

> **NCT05579119** · PHASE4 · COMPLETED · sponsor: **Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social** · enrollment: 76 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Sitagliptin 100mg
- **DRUG:** Glargine
- **DRUG:** Lispro

## Key facts

- **NCT ID:** NCT05579119
- **Lead sponsor:** Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-06
- **Primary completion:** 2023-08-14
- **Final completion:** 2023-08-24
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2023-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579119, "SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05579119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*